39 / 61
LUME-Lung 1: Tumour growth over time
•
Tumor burden was measured as sum of longest diameter of target lesions
•
Reck et al. Oral presentation at WCLC 2015.
All adenocarcinoma
patients
Patients who progressed
<9 months after start of
first-line therapy
PD as best response to
first-line therapy
Nintedanib plus docetaxel
Placebo plus docetaxel
Time since randomization in LUME-Lung 1 (months)
Sum of longest diameter of target lesions (mm
)
Nintedanib plus docetaxel
Placebo plus docetaxel
Nintedanib plus docetaxel
Placebo plus docetaxel
Treatment difference at 6
months: 19.7 mm
Treatment difference at
6 months : 16.8 mm
Treatment difference at 6
months: 9.7 mm
88.3 mm
The more aggressive the course of disease, the greater the OS-advantage
for Nintedanib + Docetaxel
OS
HR 0.83
OS
HR 0.75
OS
HR 0.62